A neurological perspective on the enhancement debate: Lessons learned from Parkinson's disease.
Cognitive enhancement is signified by adaptive behavioural change following an intervention that targets the brain. Although much of the discussion and research into cognitive enhancement focuses on the effects of neural interventions in healthy individuals, it is useful to consider evidence from clinical populations. Diseases of the central nervous system represent the primary and richest source of evidence on the effects of brain manipulations, which are in the first instance therapeutic. Parkinson's disease (PD) is used as a model for understanding the effects of pharmacological agents that target systems with a central role in cognition. The mixed outcomes of deep brain stimulation on cognition will also be discussed. By illustrating the psychopharmacological principle of diverse and malleable neurochemical optima for different cognitive functions, and the role of individual differences, it will be argued that the entire spectrum of cognitive effects in any one individual following any given manipulation, such as the administration of a drug, often includes enhancement as well as impairment. Predicting these effects represents a complex multivariate problem, and the accuracy of this predictive effort, as well as the harm prevention it connotes, is determined by our evolving understanding of the brain and cognition. A manipulation can be said to confer cognitive enhancement; however, it is argued that using the global term cognitive enhancer to refer to such a manipulation without qualification is of limited utility.
Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK angie.kehagia@gmail.com.
Angie A
AA
Kehagia
D000818:Animals; D001921:Brain / Q000187:drug effects*; D003071:Cognition / Q000187:drug effects*; D046690:Deep Brain Stimulation / Q000379:methods; D006801:Humans; D018697:Nootropic Agents / Q000627:therapeutic use*; D010300:Parkinson Disease / Q000188:drug therapy*
D018697:Nootropic Agents
COMT; Cognitive enhancement; Parkinson’s disease; dopamine; individual differences